Table 2.
Expression with clinical outcome in the Adjuvant Setting.
| Study | Sample Size | Treatment Regimen | Median DFS | Median OS | Method ERCC1 Detection | ERCC1 Positive/High-Expressing Tumors | Results | Statistical Significance |
|---|---|---|---|---|---|---|---|---|
| Sun et al. 2012 [15] | 57 | Gemcitabine-Cisplatin | - | 5-year 52.3% | IHC | 34/57 (59.6%) | Positive ERCC1 expression—Shorter survival Negative ERCC1—Prolonged DFS Negative ERCC1—Prolonged OS |
HR for death: 2.64; 95% CI 1.01–6.85; p = 0.047 p = 0.20 p = 0.034 |
| Hoffman et al. 2010 [29] | 108 | Cisplatin-Methotrexate (CM) Methotrexate, Vinblastine, Epirubicin, Cisplatin (M-VEC) |
- | - | RT-PCR | - | Low ERCC1 expression—Prolonged PFS Low ERCC1 expression—Prolonged OS |
RR = 2.24; p = 0.01; 95%CI = 1.23–4.08 RR = 1.75, p = 0.10, 95% CI = 0.89–3.44 |
| Klatte et al. 2015 [17] | 432 | Gemcitabine-Cisplatin M-VEC M-VAC |
- | - | IHC | 308 (71.3%) | ERCC1 expression—Treatment response | p = 0.88 |
DFS: disease -free survival; OS: overall survival; IHC: immunohistochemistry; RT-PCR: reverse transcription polymerase chain reaction; M-VAC: methotrexate, adriamycin, vinblastine, cisplatin; MVEC: methotrexate, vinblastine, epirubicin, cisplatin; HR: hazard ratio; CI: confidence interval.